Observational studyVox sanguinis2026
Incidence and determinants of red cell alloimmunization and autoimmunization in paediatric thalassaemia: A North Indian cohort study.
Observational study in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThalassaemia requires lifelong red cell support, which increases the risk of alloimmunization and autoimmunization. This prospective study aimed to determine the incidence of red cell sensitization and investigate the factors influencing sensitization in paediatric thalassaemia patients. MATERIALS AND
methodsA prospective observational study was conducted from April 2024 to March 2025 on 109 paediatric thalassaemia patients. At every transfusion visit, ABO/RhD typing, direct antiglobulin test and antibody screening were performed. Positive screens underwent antibody identification and provision of antigen-negative units. Demographic variables, transfusion history and product characteristics were analysed to identify significant factors influencing sensitization.
resultsAmong 109 patients (mean age 6.14 ± 4.98 years), 7.34% (n = 8) developed alloantibodies and 16.51% (n = 18) developed autoantibodies; the overall immune sensitization rate was 23.85%. Rh system antibodies predominated (75%), including anti-D, anti-E, anti-C and anti-Cw. Factors influencing alloimmunization were significantly associated with older age (p = 0.011), RhD negativity (p = 0.02) and age at first transfusion >1 year (p = 0.015). Factors influencing autoimmunization were significantly associated with later initiation of transfusion (p = 0.003). No significant associations were found with gender, ABO group or total transfusion number. Both alloimmunization (18.6 ± 10.5 days) and autoimmunization (21.9 ± 10.8 days) influenced the transfusion intervals.
conclusionThe factors influencing sensitization in paediatric thalassaemia patients were early initiation of transfusion (<1 year), RhD blood group and overall cumulative red cell exposure. Routine antibody screening at every visit and provision of Rh and Kell-matched red cell units are essential to minimize risk and enhance transfusion safety in paediatric thalassaemia patients on regular transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.